Haemonetics Corporation (NYSE:HAE) Q3 2023 Earnings Conference Call February 7, 2023 8:00 AM ET

Company Participants

David Trenk - Manager, Investor Relations

Chris Simon - Chief Executive Officer

Roy Galvin – President, Global Plasma and Blood Center

James D'Arecca - Chief Financial Officer

Conference Call Participants

Drew Ranieri - Morgan Stanley

Mike Matson - Needham & Company

Joanne Wuensch - Citi

Anthony Petrone - Mizuho

Andrew Cooper - Raymond James

Dave Turkaly - JMP

Operator

Good day, and welcome to the Haemonetics Third Quarter Fiscal '23 Conference Call and Webcast. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session, instructions will be given at that time. As a reminder, this call is being recorded.

I would now like to turn the call over to David Trenk, Manager, Investor Relations. You may begin.

David Trenk

Good morning, everyone. Thank you for joining us for Haemonetics third quarter fiscal '23 conference call and webcast. I'm joined today by Chris Simon, our CEO; Roy Galvin, President of our Global Plasma and Blood Center businesses; and James D'Arecca, our CFO.

This morning, we posted our third quarter and year-to-date fiscal '23 results to our Investor Relations website, along with updates to our fiscal '23 guidance and the analytical tables with the information that we will refer to on this call. Unless otherwise noted, all revenue growth rates we will discuss today are organic and exclude the impact of currency fluctuation, strategic exits of product lines, acquisitions and divestitures. Additionally, to help investors understand Haemonetics ongoing business performance, we will refer to non-GAAP financial measures. These measures excluded certain charges and income items. For additional details about excluded items, comparisons with the same periods in fiscal '22 and reconciliations to our GAAP results, please refer to our third quarter and year-to-date fiscal '23 earnings release posted on our IR website.

Our remarks today will also include forward-looking statements, and our actual results may differ materially from the anticipated results. Please refer to the safe harbor statement in the earnings release and other filings with the SEC for a complete list of risk factors that may impact our results. Additionally, in order to protect customer confidentiality, we will not be able to discuss any customer-specific details except as disclosed previously.

And now I'd like to turn it over to Chris.

Chris Simon

Thanks, David. Good morning, and thank you all for joining. Today, we reported third quarter organic revenue growth of 21% and adjusted earnings per diluted share of $0.85, 1% growth over a record third quarter last year.